• Corpus ID: 17811979

Long term follow-up of Thalidomide plus Interleukin-2 based therapy in metastatic renal cell cancer patients Research

@inproceedings{Amato2009LongTF,
  title={Long term follow-up of Thalidomide plus Interleukin-2 based therapy in metastatic renal cell cancer patients Research},
  author={Robert J. Amato and Muhammad Khan and Somyata Saxena},
  year={2009}
}
__________________________________________________________________________________ *Correspondence: Robert J Amato, DO, Professor, University of Texas Medical School, Department of Internal Medicine, Division of Oncology, 6410 Fannin, Suite 710, Houston, Texas 77030, USA; Tel: 832-325-7701; Fax; 713-512-7132; e-mail: Robert.Amato@uth.tmc.edu 

Figures and Tables from this paper

References

SHOWING 1-10 OF 59 REFERENCES
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
TLDR
With prolonged follow-up, treatment with high-dose recombinant IL-2 remains extremely effective for a subset of patients with metastatic renal cell carcinoma.
Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)
TLDR
An oral multi-targeted tyrosine kinase inhibitor of PDGFR and VEGFR with antiangiogenic and antitumor activity against metastatic RCC studied in 2 independent single-arm trials.
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
TLDR
High-dose IL-2 appears to benefit some patients with metastatic renal cell carcinoma by producing durable CRs or PRs, despite severe acute treatment-associated toxicities, and should be considered for initial therapy of patients with appropriately selected metastatic carcinoma.
Therapeutic options in the management of renal cell carcinoma.
  • J. Glaspy
  • Biology, Medicine
    Seminars in oncology
  • 2002
TLDR
The spontaneous regression of mRCC in some cases suggests that these tumor cells are responsive to immunologic mechanisms, and expansion of activated T cells in blood during treatment with these two cytokines seems to relate to clinical efficacy in patients with RCC.
Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
TLDR
The European experience suggests that the 5-year survival rate for metastatic renal cell carcinoma patients treated with high-dose continuous infusion IL-2 therapy is approximately 8% and that the majority of the therapeutic benefit is restricted to patients achieving a complete response.
SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.
  • R. Motzer, B. Rini, C. Baum
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
SU011248 administered in repeat cycles of 50 mg daily for 4 weeks followed by a 2-week rest period exhibits promising antitumor activity as second-line therapy for patients with metastatic RCC.
Cytokine therapy for metastatic renal cell carcinoma.
  • R. Bukowski
  • Medicine, Biology
    Seminars in urologic oncology
  • 2001
TLDR
Cytokine therapy for patients with metastatic renal cancer is based on observations suggesting this neoplasm may be responsive to immunotherapy, and individuals who are asymptomatic and have limited pulmonary or soft-tissue disease are most likely to benefit.
Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
TLDR
Several phase II studies have demonstrated that administering lower doses of IL-2 by IV bolus or continuous IV infusion or subcutaneously produces overall response rates similar to those with high-dose IL- 2 therapy; however, randomized clinical trials have not yet been completed.
Thalidomide therapy for renal cell carcinoma.
  • R. Amato
  • Medicine
    Critical reviews in oncology/hematology
  • 2003
Immunotherapy of metastatic renal cell cancer.
  • M. Fishman, J. Seigne
  • Medicine, Biology
    Cancer control : journal of the Moffitt Cancer Center
  • 2002
TLDR
O Ongoing laboratory investigation of the cause of the immune deficit in patients with metastatic renal cell cancer will result in the development of novel therapies to enhance tumor cell recognition as well as host antitumor response.
...
1
2
3
4
5
...